Abstract 4860
Background
BC patients who have evidence of bone metastases should be treated with BMAs in order to reduce skeletal related events. ONJ is a serious complication associated the use of BMAs. In this large population-based study we evaluate the patterns of use of BMAs and ONJ rates in a cohort of older BC patients.
Methods
Patients diagnosed with de novo metastatic BC between 2007-2013 were identified in the SEER-Medicare database. We identified the presence of bone metastases using specific PEDSF variables and claims. All patients were required to receive systemic anticancer therapy within one year of diagnosis. HCPCS codes were used to identify the use of BMAs within 1 year of cancer diagnosis, ONJ was identified using an established ICD-9 codes. Descriptive statistics and regression models were used.
Results
A total of 1,528 patients were included. The median age of the cohort was 74 yo. Within one year of diagnosis of bone metastases 71.1% of the patients received BMAs (68% bisphosphonates, 27% denosumab, 5% both). Older patients (OR = 0.64; 95%CI 0.46-0.89), those with more comorbidities (OR = 0.61; 95%CI 0.43-0.85) or with full/partial state buy-in (OR = 0.65; 95%CI 0.49-0.87) -surrogate for poverty- were less likely to receive BMAs. Nineteen cases of ONJ were identified, all of them occurred among BMAs-treated patients (1.7%), the 2-year and 4-year cumulative rates were 1.4% and 4.0%, respectively. Similar rates of ONJ were observed between patients treated with bisphosphonates and denosumab. Median duration of BMA therapy among patients who developed ONJ was 20 months (IQR 10-43). No clinical predictors of ONJ were identified.
Conclusions
In this large, nationally-representative cohort, the majority of the BC patients with evidence of bone metastases received treatment with BMA according to current guidelines. Similar rates of ONJ were observed among bisphosphonates and denosumab users. ONJ occurred in approximately 2% of this SEER-Medicare population of patients with BC and bone metastases treated with BMA. Our findings are of significant value since they reflect the patterns of care and complications associated with these commonly used agents in the general population.
Clinical trial identification
Legal entity responsible for the study
Mariana Cgavez Mac Gregor.
Funding
CERCIT, Sudan G. Komen.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1449 - Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67 and molecular subtype.
Presenter: Bernardo Rapoport
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4023 - The accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node positive breast cancer patients: A single institution experience
Presenter: Narges Sistany Allahabadi
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4707 - Index BRCA1/2 testing under a multidisciplinary program
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3393 - BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
Presenter: Alex Friedlaender
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3175 - PALB2 germ-line mutations in Russian breast cancer patients: identification of recurrent alleles and analysis of phenotypic characteristics of the tumors
Presenter: Evgeny Imyanitov
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3027 - Landscape of germline mutations in hereditary breast and ovarian cancer (HBOC) patients in Russia revealed by target panel sequencing
Presenter: Elena Shagimardanova
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4963 - Lynch syndrome-associated hereditary mutations cause breast and ovarian cancer: results from Russian Heredetary Oncogenomics project
Presenter: Marat Gordiev
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2916 - Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)
Presenter: Nathalie OLYMPIOS
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2400 - Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study
Presenter: Esther Pohl
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1345 - BRCA1/BRCA2 Predictive Genetic Testing in an Irish Population: A Missed Opportunity
Presenter: David O Reilly
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract